Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) - Equities research analysts at Leerink Partnrs reduced their Q2 2025 EPS estimates for Design Therapeutics in a research note issued to investors on Wednesday, May 7th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings of ($0.33) per share for the quarter, down from their prior estimate of ($0.26). The consensus estimate for Design Therapeutics' current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for Design Therapeutics' Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.30) EPS and FY2026 earnings at ($1.49) EPS.
Design Therapeutics (NASDAQ:DSGN - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.03).
Design Therapeutics Trading Down 10.1%
DSGN traded down $0.36 during trading hours on Monday, hitting $3.21. 68,723 shares of the company's stock were exchanged, compared to its average volume of 187,472. Design Therapeutics has a 12-month low of $2.60 and a 12-month high of $7.77. The firm has a 50 day moving average of $3.98 and a 200 day moving average of $4.93. The firm has a market cap of $182.23 million, a P/E ratio of -3.78 and a beta of 1.77.
Institutional Investors Weigh In On Design Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Invesco Ltd. purchased a new position in Design Therapeutics during the 4th quarter worth $71,000. ProShare Advisors LLC purchased a new stake in Design Therapeutics during the fourth quarter worth about $71,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Design Therapeutics in the fourth quarter valued at about $74,000. Kennedy Capital Management LLC purchased a new stake in shares of Design Therapeutics in the fourth quarter valued at about $88,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Design Therapeutics in the fourth quarter valued at about $109,000. 56.64% of the stock is currently owned by institutional investors and hedge funds.
About Design Therapeutics
(
Get Free Report)
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Featured Stories
Before you consider Design Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Design Therapeutics wasn't on the list.
While Design Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
